At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
EQ Equillium Inc.
Pre-Mkt 03-19 09:23:16 EDT
2.13
-0.02
-0.93%
盘前2.08
-0.05-2.27%
09:20 EDT
High2.24Low2.06Vol402.90K
Open2.15D1 Closing2.15Amplitude8.60%
Mkt Cap129.70MTradable Cap92.71MTotal Shares60.89M
T/O851.79KT/O Rate0.93%Tradable Shares43.52M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

EQ Resources Extinguishes A$7.25m Oaktree Loan via Share Issue
TIPRANKS  ·  06:30
EQ Resources Extinguishes A$7.25m Oaktree Loan via Share Issue
EQ Resources Seeks ASX Quotation for 145 Million New Shares
TIPRANKS  ·  06:30
EQ Resources Seeks ASX Quotation for 145 Million New Shares
EQ Resources Seeks ASX Quotation for 905,556 New Ordinary Shares
TIPRANKS  ·  06:29
EQ Resources Seeks ASX Quotation for 905,556 New Ordinary Shares
Assessing EQ Resources (ASX:EQR) Valuation After Half Year Earnings And Narrower Net Loss
Simply Wall St.  ·  06:12
Assessing EQ Resources (ASX:EQR) Valuation After Half Year Earnings And Narrower Net Loss
Equillium to Join Fireside Chat at the Roth Conference
Reuters  ·  03-18 20:30
Equillium to Join Fireside Chat at the Roth Conference
Why Brightstar, EQ Resources, Novonix, and Pro Medicus shares are falling today
MotleyFool  ·  03-18 11:02
Why Brightstar, EQ Resources, Novonix, and Pro Medicus shares are falling today
EQ Resources Reaffirms Robust Tungsten Resource Base at Investor Conference
TIPRANKS  ·  03-18 08:52
EQ Resources Reaffirms Robust Tungsten Resource Base at Investor Conference
Equillium COO Christine Zedelmayer disposes of USD 300,788 in common shares
Reuters  ·  03-17 06:54
Equillium COO Christine Zedelmayer disposes of USD 300,788 in common shares
EQ Resources Shareholders Back Capital Issuance and Incentive Plans at Extraordinary Meeting
TIPRANKS  ·  03-16
EQ Resources Shareholders Back Capital Issuance and Incentive Plans at Extraordinary Meeting
EQ Resources Trims Option Pool With Cessation of 275,818 Securities
TIPRANKS  ·  03-16
EQ Resources Trims Option Pool With Cessation of 275,818 Securities
EQ Resources issues new shares and confirms compliance in cleansing notice
TIPRANKS  ·  03-16
EQ Resources issues new shares and confirms compliance in cleansing notice
EQ Resources (ASX:EQR) H1 Loss Narrows Sharply, Testing Bearish Profitability Narratives
Simply Wall St.  ·  03-15
EQ Resources (ASX:EQR) H1 Loss Narrows Sharply, Testing Bearish Profitability Narratives
Why EQ Resources (ASX:EQR) Is Up 5.8% After Narrowing Half-Year Loss On Stronger Revenue – And What's Next
Simply Wall St.  ·  03-14
Why EQ Resources (ASX:EQR) Is Up 5.8% After Narrowing Half-Year Loss On Stronger Revenue – And What's Next
Equillium Initiated at Buy by Roth Capital
Dow Jones  ·  03-14
Equillium Initiated at Buy by Roth Capital
Equillium agrees USD 35 million unregistered share sale with RA Capital Management
Reuters  ·  03-13
Equillium agrees USD 35 million unregistered share sale with RA Capital Management
Equillium Announces $35 Million Financing With Ra Capital Management
THOMSON REUTERS  ·  03-13
Equillium Announces $35 Million Financing With Ra Capital Management
Equillium Inc - Net Proceeds Expected to Extend Cash Runway Into 2029
THOMSON REUTERS  ·  03-13
Equillium Inc - Net Proceeds Expected to Extend Cash Runway Into 2029
Equillium Inc - to Use Net Proceeds to Advance EQ504 Clinical Development
THOMSON REUTERS  ·  03-13
Equillium Inc - to Use Net Proceeds to Advance EQ504 Clinical Development
Press Release: Equillium Announces $35 Million Financing with RA Capital Management
Dow Jones  ·  03-13
Press Release: Equillium Announces $35 Million Financing with RA Capital Management
Roth Capital Partners Initiates Equillium at Buy With $12 Price Target
MT Newswires Live  ·  03-13
Roth Capital Partners Initiates Equillium at Buy With $12 Price Target

Introduction

Company Name.
Equillium Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Issue price:
--